The dual Syk/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia

PURPOSE: B-cell receptor (BCR)-associated kinase inhibitors such as ibrutinib have revolutionised the treatment of chronic lymphocytic leukemia (CLL). However, these agents are not curative and resistance is already emerging in a proportion of patients. Interleukin-4 (IL-4), expressed in CLL lymph n...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Blunt, Matthew D, Koehrer, Stefan, Dobson, Rachel, Larrayoz, Marta, Wilmore, Sarah, Hayman, Alice, Parnell, Jack, Smith, Lindsay, Davies, Andrew, Johnson, Peter W, Conley, Pamela B, Pandey, Anjali, Strefford, Jon C, Stevenson, Freda K, Packham, Graham, Forconi, Francesco, Coffey, Greg, Burger, Jan A, Steele, Andrew J
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5417366/
https://ncbi.nlm.nih.gov/pubmed/27697994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1662
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi